Cleave Therapeutics
Signal active
Organization
Contact Information
Overview
Cleave Therapeutics develops oncology pharmaceuticals designed to target neurodengeneration and pathways used by cancer cells to grow. The company is engaged in the discovery of novel, small-molecule drugs that affect protein-degradation pathways, upon which cancer cells depend for survival, enabling patients to get cured from cancer.
About
Industries
Biotechnology, Health Care, Biopharma
Founded
2010
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Cleave Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Biopharma sector. The company focuses on Biotechnology and has secured $4.8B in funding across 48 round(s). With a team of 11-50 employees, Cleave Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Cleave Therapeutics, raised $42.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
4
Investors
6
Lead Investors
0
Total Funding Amount
$101.0M
Details
4
Cleave Therapeutics has raised a total of $101.0M in funding over 4 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2019 | Late Stage Venture | 12.0M | ||
| 2016 | Early Stage Venture | 37.0M | ||
| 2013 | Early Stage Venture | 10.0M | ||
| 2011 | Early Stage Venture | 42.0M |
Investors
Cleave Therapeutics is funded by 32 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Astellas Venture Management | - | FUNDING ROUND - Astellas Venture Management | 37.0M |
| Marc Singer | - | FUNDING ROUND - Marc Singer | 37.0M |
| Cleave Therapeutics | - | FUNDING ROUND - Cleave Therapeutics | 37.0M |
| OUP (Osage University Partners) | - | FUNDING ROUND - OUP (Osage University Partners) | 37.0M |
Recent Activity
There is no recent news or activity for this profile.